F. Stephen Hodi, MD is the director of both the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women’s Cancer Center, the Sharon Crowley Martin Chair in melanoma at Dana-Farber Cancer Institute, and a professor of medicine at Harvard Medical School. Stephen is a member of the American Society of Clinical Oncology, the Eastern Cooperative Oncology Group Melanoma Committee, the Society for Immunotherapy of Cancer, and a founding member of the Society for Melanoma Research. He is internationally known for his work leading to FDA approval of ipilimumab, a checkpoint inhibitor used to treat melanoma. He led the first human trial, and later the Phase 3 registration trial, for ipilimumab. More recently, Stephen has focused on the clinical development of PD-1 and PD-L1 checkpoint inhibitors, and led groundbreaking trials that combined checkpoint blockade drugs with other anti-angiogenesis agents. His work has led to improved treatments for lung and kidney cancer, as well as melanoma.
Stephen earned his MD from Weill Cornell Medical College of Cornell University. He completed his postdoctoral training in internal medicine at the Hospital of the University of Pennsylvania, and medical oncology training at Dana-Farber Cancer Institute.